

DAFTAR PUSTAKA

- Abbara, A., Chitty, S., Roe, J. K., Ghani, R., Collin, S.M, Ritchie, A., Kon, O. M., Dzvova, J., Davidson, H., Edward, T. E., Hateley, C., Routledge, M., Buckey, J., Davidson, R. N., John, L., 2017. Drug Induced liver Injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. *BMC Infectious Disease*, Vol. 17, No. 231, p 1-9
- Abbas, A., 2017. Monitoring efek samping obat anti-tuberkulosis (OAT) pada pengobatan tahap intensif penderita TB Paru di Kota Makasar. *Journal of Agromedicine and Medical Science*, Vol. 3, No. 1, hal.19-24
- Abbas, A., Lichtman, A. H., Pillai, S., 2015. *Basic Immunology: Functions and Disorders of the Immune Systems 5th Ed.* Canada: Elsevier Inc.
- Adeyemo, A. A., Oluwatosin, O., Omotade, O. O., 2016. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. *Springer Plus*, Vol. 5, No. 758, p. 1-9
- Adiody, S., Sivakumar, P., Saji, J. P., 2018. A Study Profile on Adverse Drug Reactions to First-Line Antitubercular Drugs in Extra Pulmonary TB. *Journal of Evolution of Medical and Dental Science*. Vol. 7, No. 9, p. 1111-1113
- Adrian, T. B. R., Montiel, J. L., Fernandez, G., Valecillo, A., 2015. Role of Cytokines and other Factors Involved in Mycobacterium Tuberculosis Infection. *World Journal of Immunology*, Vol. 5, No. 1, p. 16-50

- Adriztina, I., Adnan, A., Haryuna, S. H., Siagian, P., Sarumpaet, S., 2014. Gangguan pendengaran dan keseimbangan pada penderita tuberkulosis yang mendapat pengobatan antituberkulosis kategori 1 dan 2. *Jurnal Kesehatan Nasional*, Vol. 8, No. 8, hal. 430-436
- Alvarez, G. G., Roth, V. R., Hodge, W., 2008. Ocular tuberculosis: diagnostic and treatment challenges. *International Journal of Infectious Disease*, Vol. 13, p. 432-435
- Alghamdi, W. A., Al-Shaer, M. H., Peloquin, C. A., 2018. Protein Binding of First-Line Antituberculosis Drugs. *Antimicrobial Agents and Chemotherapy*, Vol. 62, No. 7, p. 1-7
- Arbex, M. A., Varella, M. C. L., de Siqueira, H. R., de Mello, F. A. F., 2010. Antituberculosis drugs: Drug interactions, adverse effect, and use in special situations. Part 1: First-line drugs. *Jornal Brasileiro de Pneumologia*, Vol. 36, No. 5, p. 626-640
- Arbex, M. A., Varella, M. C. L., de Siqueira, H. R., de Mello, F. A. F., 2010. Antituberculosis drugs: Drug interactions, adverse effect, and use in special situations. Part 2: Second-line drugs. *Jornal Brasileiro de Pneumologia*, Vol. 36, No. 5, p. 641 – 656
- Athira, B., Manju, C. S., Jyothi, E., 2015. A Study on Adverse drug recations to first line antitubercular drug in DOTS therapy. *International Journal of Pharmacology and Clinical Science*, Vol. 4, No. 1, p. 7-11
- Atif, M., Sulaiman, S. A. S., Shafie, A. A., Babar, Z. U., 2015. Duration of Treatment in Pulmonary Tuberculosis: are international guideline on the management of tuberculosis missing something?. *Public Health*, p. 1-6

- Barret, K., Brooks, H., Boitano, S., Barman, S., 2010. *Ganong's Review of Medical Physiology 23th Ed.* California: McGraw-Hill Companies, Inc, p. 443-446
- Biswas, A and Dutta, N., 2018. Role of Betahistine in the Management of Vertigo. *Indian Society of Otolology*, Vol. 1, p. 51-57
- Boveneind, N., Daskapan, A., Kosterink, J. G. W., Werf, T. S., Hof, S., Alffenaar, J., 2016. Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting. *Plos One*, Vol. 11, No. 11, p. 1-12
- Brunton, L., Chabner, B., Knollman, B., 2011. *Goodman & Gilman's The Pharmacologic Basic of Therapeutics 12th Ed.* California: The McGraw-Hill Company, p. 1549-1568
- Center for Disease Control and Prevotion, 2013. Chapter 2: Transmission and Pathogenesis of Tuberculosis. In: *Core Curriculum on Tuberculosis: What The Clinician Should Know Sixth Edition.* Division of Tuberculosis Elimination, p. 19-43
- Chetty, S., Ramesh, M., Pillary, A. P., and Soliman., 2017. Recent advorcements in the development of antituberculosis drugs. *Bioorganic & Medicinal Chemistry Letters*, Vo. 27, p. 370-386
- Chrousos, G. P., 2012. Chapter 39: Adrenocorticosteroids & Adrenocortical Antagonist. In: Katzung, B. G., Masters, S. B., Trevor, A. J. (Eds.). *Basic & Clinical Pharmacology*, Ed. 12th. United States: The McGraw-Hill Companies p. 697-711
- Chung, H., Yoon, Y. H., Hwang, J. J., Cho, K. S., Koh, J. Y., Kim, J., 2009. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells, *Toxicology and Applied Pharmacology*, Vol. 235, p. 162-170

- Cureoglu, S., Schachern, P. A., Paparella, M. M., 2003. Effect of parenteral aminoglycoside administration on dark cells in the crista ampullaris. *Archives of Otolaryngol Head and Neck Surgery*, Vol. 129, p. 626-628
- Dargie, B., Tesfaye, G., Worku, A., 2016. Prevalence and associated factors of undernutrition among adult tuberculosis patients in some selected public health facilities of Addis Ababa, Ethiopia: a cross-sectional study. *Biomedical Central Nutrition*, Vol. 2, No. 7
- Deck, D. H., and Winston, L. G., 2012. Chapter 47: Antimycobacterial drugs. In: Katzung, G., Masters, Susan, B., Trevor, Anthony, J. (Eds.). *Basic & Clinical Pharmacology 12th Edition*. New York: The McGraw-Hill Companies Inc, p. 839-847
- Departemen Kesehatan Republik Indonesia, 2005. *Pharmaceutical Care untuk Penyakit Tuberkulosis*. Jakarta: Departemen Kesehatan Republik Indonesia
- Departemen Kesehatan Republik Indonesia, 2013. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis*. Jakarta: Departemen Kesehatan Republik Indonesia
- Department Health Republic of South Africa, 2014. *National Tuberculosis Management Guidelines*. South Africa: Departement Health Republic of South Africa
- Devi, H. J, G., 2014. Complications of Pulmonary Tuberculosis. In *Tuberculosis: a comprehensive clinical reference*. iConcept Press
- Diana, Karema-K, AMC., Matheos, JC., 2013. Pengaruh Obat Anti Tuberkulosis Kombinasi Dosis Tetap terhadap Kadar Asam

- Urat. *Cermin Dunia kedokteran-205*, Vol. 40, No. 6, hal. 413-415
- Dooley, K. E., Chaisson, R. E., 2009. Tuberculosis and diabetes mellitus: convergence of two epidemics. *The Lancet Infectious Disease*. Vol. 9, No. 737-746
- Fauziah, N., Ahmad, I., Ibrahim, A., 2014. Karakteristik dan Analisis Drug Related Problems (DRPs) Pasien Penderita Tuberkulosis di Puskesmas Temindung Samarinda Kalimantan Timur. *Journal of Tropical Pharmacy Chemistry*, Vol. 2, No. 5, hal. 252-258
- Flomenbaum, N. E., Goldfrank, L. R., Hoffman, R. S., Howlan, M. A., Lewin, N. A., Nelson, L. S., 2006. *Goldfrank's Toxicologic Emergencies*, Ed 8th. New York: McGraw-Hill, p.3405-3433
- Fuentes, Z. M., and Caminero, J. A., 2006. Controversies in the treatment of extrapulmonary tuberculosis. *Archivos de Bronconeumologia*, Vol. 42, No. 4, p. 194-201
- Gulbay, B. E., Gurkan, O. U., Yildiz, O. A., Onen, Z. P., Erkekol, F. O., Baccioglu, A., Acican, T., 2006. Side Effect due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospital patients for tuberculosis. *Respiratory Medicine*, Vol. 100, p. 1834-1842
- Gunal, S., Yang, Z., Agarwal, M., Koroglu, M., Arici, Z. K., Durmaz, R., 2011. Demographic and microbial characteristics of extrapulmonary tuberculosis cases diagnosed in Malatya, Turkey, 2001-2007. *BMC Public Health*, Vol. 11, No. 154, p. 1-8
- Guo, H., Hassan, H. M., Ding, P., Wang, S., Chen, X., Wang, T., Sun, L., Zhang, L., Jiang, Z., 2017. Pyrazinamide-induced

- hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2 α -ATF4-CHOP pathway. *Toxicology*, Vol. 378, p. 65-75
- Gupta, P. R., 2004. Difficulties in Managing Lymph Node Tuberculosis. *Lung India*, Vol. 21, p. 50-53
- Gupta, S., Singh, V. J., Bhatia, G., Dhuria, K., 2014. Primary tuberculosis of the breast manifested as abscess: a rare case report. *The Indonesian Journal of Internal Medicine*, Vol. 46, No. 1, p.51-52
- Gupta, V., Gupta, A., Rao, N. A., 2007. Intraocular tuberculosis-an update. *Survey of Ophthalmology*, Vol. 52, No. 6., p.561-587
- Hastari, V. I., 2018. *Implementasi layanan kefarmasian dalam mengatasi problema terkait obat anti tuberkulosis lini pertama pada pasien tuberkulosis fase intensif* [Tesis]. Surabaya: Universitas Airlangga
- Heemskerk, D., Caws, M., Marais, B., Farrar, J., 2015. *Tuberculosis in Adults and Children*. Switzerland: Springer International Publishing
- Houston, A., Macallan, D. E., 2014. Extrapulmonary tuberculosis. *Medicine*, Vol. 42, No. 1, p. 18-22
- Huang, S., Chien J., Tsai, R., 2015. Ethambutol induces impaired autophagic flux and apoptosis in the rat retina, *The Company of Biologist*, Vol. 8, p.977-987
- Irianti, T., Kuswendi, Yasin, N. M., Kusumaningtyas, R. A., 2016. *Mengenal Anti-Tuberkulosis*. Yogyakarta: Fakultas Farmasi UGM
- Jorstad, M. D., Dyrhol-Riise, A. M., Abmus, J., Marijani, M., Sviland, L., Mustafa, T., 2019. Evaluation of Treatment Response in

- Extrapulmonary Tuberculosis in a Low-Resouce Setting. *BMC Infectious Disease*, Vol. 19, No. 426, p. 1-9
- Kadhiravan, T., and Deepanjali, S., 2010. Role of corticosteroid in the treatment of tuberculosis: an evidence-based update. *The Indian Journal of Chest Disease & Allied Science*, Vol. 52, p.153-158
- Kembuan, 2009. Patofisiologi Vertigo. *Jurnal Tumou Tou*, Vol. 1, No. 1, hal. 31-36
- Kementerian Kesehatan RI. 2014. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan
- Kementerian Kesehatan RI. 2016. *Petunjuk Teknis Manajemen dan Tatalaksana TB Anak*. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit
- Kementerian Kesehatan RI. 2018. *Infodatin Tuberkulosis*. Jakarta: Kementerian Kesehatan RI
- Khalili, H., Dashti-Khavidaki, S., Rasoolinejad, M., Rezaie, L., Etminani, M., 2009. Anti-tuberculosis drug related hepatotoxicity: incidence, risk factors, pattern of changes in liver enzyme and outcome. *DARU Journal of Faculty of Pharmacy*, Vol. 17, No. 3
- Kim, M. J., Kim, H. R., Hwang, S. S., Kim, Y. W., Han, S. K., Shim, Y. S., Yim, J. J., 2009. Prevalence and Its Predictors of Extrapulmonary Involment In Patient With Pulmonary Tuberculosis. *Journal of Korean Medical Science*, Vol. 24, p. 237-241
- Kishore, P. V., Palaian, S., Paudel, R., Mishra, P., Prabhu, M., Shankar, P. R., 2007. Drug induced hepatitis with anti-tubercular

- chemotherapy: challenges and difficulties in treatment. *Kathmandu University Medical Journal*, Vol. 5, No. 2, p. 256-260
- Koul, P. A., 2015. Ocular Toxicity with ethambutol therapy: Timely recaution. *Lung India*, Vol. 32, p. 1-3
- Kulchavenya, Ekaterina. 2014. Extrapulmonary tuberculosis: are statistical reports accurate?. *Therapeutic Advances in Infectious Disease*, Vol. 2 No. 2, p. 61-70
- Kumar, V., Abbas, A. K., Aster, J. C., 2013. *Robbins Basic Pathology 9th Ed.* Philadelphia: Elsevier
- Kurniangsih, L., Sudirman, I., Utamingrum, W., 2010. Identifikasi Drug Related Problems (DRPs) Pengobatan Tuberkulosis Pada Pasien Rawat Jalan di RSUD Kardinah Kota Tegal Tahun 2009. *Pharmacy*, Vol. 7, No. 3., hal.50-58
- Lee, J. Y., 2015. Diagnosis and treatment of extrapulmonary tuberculosis. *Tuberculosis and Respiratory Disease*, Vol. 78, p.47-55
- Lehloenya, R. J., Dheda, K., 2012. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of art and into the future. *Expert Review of Anti-infective Therapy*, Vol. 4, No. 2, p. 1-12
- Lin, C., Chen, T., Lu, P., lai, C., Yang, Y., Lin, W., Huang, M., Chen, Y., 2013. Effect of Gender and Age on Development of Concurrent Extrapulmonary Tuberculosis in Patient With Pulmonary Tuberculosis: A Population Based Study. *Plos One*, Vol. 8, No. 5, p. 1-9
- Lin, J. N., Lai, C. H., Chen, Y. H., Lee, S. S. J., Tsai, S. S., Huang, C. K., Chung, H. C., 2009. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. *The*

International Journal of Tuberculosis and Lung Disease,
Vol. 13, No. 5, p. 620-625

- Lullman, H., Mohr, K., Hein, L., Bieger, D., 2005. *Color Atlas of Pharmacology*, Ed 3rd. New York: Thieme Stuttgart
- Mattos, I. G., Ribeiro, M. O., Netto, I. C., Azevedo, P. A., 2006. Tuberculosis: A Study of 111 Cases in an Area of High Prevalence in the Extreme South of Brazil. *The Brazilian Journal of Infectious Disease and Contexto Publishing*. Vol. 10, No. 3, p. 194-198
- Mayosi, B. M., Ntsekhe, M., Bosch, J., Pandie, S., Jung, H., Gumedze, F., Pogue, J., Thabane, L., Smieja, M., Francis, V., Joldersma, L., Thomas, K. M., Thomas, B., Awotedu, A. A., Magula, N. P., Naidoo, D. P., Damasceno, A., Banda, A. C., Brown, B., Manga, P., Kirenga, B., Mondo, C., Mntla, P., Tsitsi, J. M., Peters, F., Essop, M. R., Russel, J. B. W., Hakim, J., Matenga, J., Barassa, A. F., Sani, M. U., Olunga, T., Ogah, O., Ansa, V., Aje, A., Danbauchi, S., Ojji, D., Yusuf, S., 2014. Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis, *The New England Journal of Medicine*, Vol. 12, No. 371, p. 1121-1130
- McQuaid, K. R., 2012. Chapter 62: Drugs Used in Treatment of Gastrointestinal Disease. In: Katzung, G., Masters, Susan, B., Trevor, Anthony, J. (Eds.). *Basic & Clinical Pharmacology 12th Edition*. New York: The McGraw-Hill Companies Inc, p. 1081-1110
- Mehraj, J., Khan, Z. Y., Saeed, D. K., Shakoor, S., Hasan, R., 2016. Extrapulmonary tuberculosis among females in South Asia-gap analysis. *International Journal of Mycobacteriology*, Vol. 525

- Momekov, G., Ferdinandov, D., Voynikov, Y., Stavrakov, G., Peykov, P., 2014. Pyrazinamide-pharmaceutical, biochemical and pharmacological properties and reappraisal of its role in the chemotherapy of tuberculosis, *Pharmacia*, Vol. 61, No. 1, p. 38-67
- Nahid, P., Hopewell, P. C., 2017. Tuberculosis Treatment. *International Encyclopedia of Public Health*, Vol. 7, No. 2, p. 267-276
- Nanda, G. S., Singh, H., Sharma, B., Arora, A., 2016. Adverse reactions due to Directly Observed Treatment Short Course Therapy: an Indian Prospective Study. *International Archives of Integrated Medicine*, Vol. 3, No. 1., p. 6-12
- Ningrum, V. D. A., Megasari, A., Hanifah, S., 2010. Hepatotoksisitas pada pengobatan tuberkulosis di RSUD Tangerang-Indonesia, *Jurnal Ilmiah Farmasi*, Vol. 7, No. 1, hal. 39-47
- Novialdi dan Triola, S., 2014. Penatalaksanaan tuberkulosis laring. *Jurnal Kesehatan Andalas*, Vol. 3, No. 2., hal. 270-277
- Okamura, K., Nagata, N., Wakamatsu, K., Yonemoto, K., Ikegame, S., Kajiki, A., Takayama, K., Nakanishi, Y., 2013. Hypoalbuminemia and Lymphocytopenia are Predictive Risk Factor for In-hospital Mortality in Patient with Tuberculosis. *Internal Medicine*, Vol. 52, p. 439-444
- Park, J., Choi, Y.K., Lee, J., Kim, S., Lee, S., Won, Y., Yun, S., 2009. Psoriasiform drug eruption induced by antituberculosis medication: potential role of plasmacytoid dendritic cells. *Acta Dermato-Venereologica*, Vol. 90, p. 305-306
- Pascual-Pareja, J. F., Carrillo-Gomez, R., Hontanon-Antonana, V., 2017. Treatment of pulmonary and extrapulmonary tuberculosis.

Enfermedades Infecciosas y Microbiologia Clinica, 1770 p.
10

- Pepa, C. D., Guidetti, G., Eandi, M., 2006. Betahistine in the treatment of vertiginous syndromes: a meta-analysis. *Acta Otorhinolaryngologica Italica*, Vol. 26, p. 208-215
- Peloquin, C. A., 2005. Chapter 110: Tuberculosis. In: Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., and Posey, L. M. (Eds.). *Pharmacotherapy: A Pathophysiologic Approach 6th Edition*. United State of America: The McGraw-Hill Education. p. 2015-2034
- Perhimpunan Dokter Paru Indonesia, 2011. *Pedoman Diagnosis dan Penatalaksanaan Tuberculosis di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia
- Pham, A. Q., Doan, A., Andersen, M., 2014. Pyrazinamide-Induced Hyperuricemia. *Pharmacy and Therapeutics Journal*. Vol. 39, No. 10, p. 695-715
- Pham, Dinh-Duy., Fattal, E., Tsapis, N., 2015. Pulmonary drug delivery system for tuberculosis treatment. *International Journal of Pharmaceutics*, Vol. 478, p. 517-529
- Pharmaceutical Care Network Europe, 2017. *PCNE Classification for Drug Related Problems V8.02*, Pharmaceutical Care Network Europe
- Pollet, S., Banner, P., Sullivan, M. V. N., Ralph, A. P., 2016. Epidemiology, Diagnosis and Management of Extra-Pulmonary Tuberculosis in a Low-Prevalence Country: A Four Year Retrospective Study in an Australian Tertiary Infectious Disease Unit. *Plos One*, Vol. 11, No. 3., p. 1-15

- Porfenov, V. A., Golyk, V. A., Matsnev, E., Morozoa, S. V., Malnikov, O. A., Altenonko, L. M., Sigaleva, E. E., Situkho, M. I., Asaulenko, O. I., Papovych, V. I., Zamergrad, M. V., 2017. Effectiveness of betahistine (48 mg/day) in patient with vestibular vertigo during routine practice: The VIRTUOSO study. *Plos One*, Vol. 12, No. 3, p. 1-11
- Prameswari, A., 2018. The Evaluation of Direct Observed Treatment Short-Course (DOTS) Implementation for TB in hospital X. *Jurnal Medicoeticolegal dan Manajemen Rumah Sakit*, Vol. 7, No. 2, hal. 93-101
- Prasad, K., Singh, M. B., Ryan, H., 2016. Corticosteroids for managing tuberculous meningitis, *Conchrane Infectious Disease Group Issue 4*. New Jersey: John Wiley & Sons Ltd
- Prastowo, A., Lestariana, W., Nurdjanah, S., Sutomo, R., 2016. Efektifitas Pemberian Ekstra Putih Telur Terhadap Peningkatan Kadar Albumin dan IL-6 pada Pasien Tuberkulosis dengan Hipoalbumin. *Jurnal Kesehatan*, Vol. 1., No. 1., hal. 10-18
- Ramappa, V., Aithal, G. P., 2012. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. *Journal of Clinical and Experimental Hepatology*, Vol. 48, p. 1-13
- Ramirez-Lapausa, M., Menendez-Saldana, A., Noguerado-Asensio, A., 2015. Extrapulmonary tuberculosis: an overview. *Revista Española de Sanidad Penitenciaria 2015*, Vol. 17, p. 3-11
- Ravikumar, P., Bai, P. G., 2017. A study on treatment outcome and adverse drug reactions among extra pulmonary tuberculosis patients treated under DOTS in a tertiary care hospital. *International Journal of Basic & Clinical Pharmacology*, Vol. 2., No. 1, p. 48-52

- Reither, R. J., Tan, D. X., Korkmaz, A., Fuentes-broto, L., 2011. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin, *Journal of Physiology and Pharmacology*, Vol. 62, No. 2., p. 151-157
- Ryan, H., Yoo, J., Darsini, P., 2017. Corticosteroids for tuberculous pleurisy, *Cochrane Infectious Disease Grup Issue 3*. New Jersey: John Wiley & Sons Ltd
- Saha, A., Shanthi, M., Winston, B., Das, S., Kumar, A., Michael, J. S., Balamugesh, T., 2016. Prevalence of Hepatotoxicity From Antituberculosis Therapy: a five year experience from south india. *Journal of Primary Care & Community Health*, Vol. 7, No. 3., p. 171-174
- Sari, I. D., Yuniar, Y., Syaripuddin, M., 2014. Studi Monitoring Efek Samping Obat Antituberkulosis FDC Kategori 1 di Provinsi Banten dan Provinsi Jawa Barat. *Media Litbangkes*, Vol. 24, No. 1, hal. 28 – 35
- Satish, B., 2017. Isoniazid Toxicity. *Journal of Drug Design and Research*, Vol. 4, No. 7, p. 1-8
- Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., Bernando, J., Venkataramanan, R., Sterling, T. R., 2006. American Thoracic Society Document: An official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. *American Journal of Respiratory and Critical Care Medicine*, Vol. 174, p. 935-952
- Schatz, S. N., and Weber, R. J., 2015. Adverse Drug Reactions. *Pharmacotherapy Self-Assessment Program: CNS/Pharmacy Practice.*, p. 5-26

- Schimer, B. P., and Funder, J. W., 2011. Chapter 42: ACTH, Adrenal Steroids, and Pharmacology of the Adrenal Cortex. In: Brunton, L., Chabner, B., Knollman, B., (Eds). ***Goodman & Gilman's The Pharmacologic Basic of Therapeutics 12th Ed.*** California: The McGraw-Hill Company, p. 1209-1234
- Scott, A. G., Scott, G. N., 2013. Mechanisms of Drug Interactions. ***Pharmacy Tech TopicsTM***, Vol. 18 No. 3
- Shareef, J., Nandakumar, U. P., Bhat, M., 2018. A Study on Assessment of Adverse Drug Reactions in Patient with Tuberculosis in a Tertiary Care Teaching Hospital. ***Journal of Applied Pharmaceutical Science***, Vol. 8, No. 4, pp. 099-104
- Sharma, S. K., Ryan, H., Khaparde, S., K. S. Sachdeva, Sing, A. D., Mohan, A., Sarin, R., Paramasivan, C. N., Kumar, P., Nischal, N., Khatiwada, S., Garner, P., Tharyan, P., 2017. Index-TB Guidelines: Guidelines on extrapulmonary tuberculosis for india. ***Indian Journal Medical Respiratory*** 145, pp. 448-463
- Shelat, V. G., Pandya, G. J., Dixit, R., 2005. Tuberculous mastitis with rib erosion. ***Journal Indian Academy of Clinical Medicine***, Vol. 6., No. 1, p. 82-85
- Shih, T, Pai, C., Yang, P., Chang, W., Wang, N., Hu, O., 2013. A Novel Mechanism Underlies the Hepatotoxicity of Pyrazinamide. ***Antimicrobial Agent and Chemotherapy***, Vol. 57, No. 4, p 1685-1690
- Shivaraj, Dr. G., Muralikrishna, Dr. K., Nijeesh C. H., Laloo F., Baburaja B., Dodddayya, Dr. H., 2017. Study on Drug Related Problems in Tuberculosis Patients with Comorbidities in a Tertiary Care Teaching Hospital, ***European Journal of Pharmaceutical and Medicinal Research***, Vol. 4, No. 9, p. 756-767

- Singh, A., Prasad, R., Balasubramanian, V., Gupta, N., Gupta, P., 2015. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. *Clinical Epidemiology and Global Health*, Vol. 10, No. 5, p. 1-11
- Singh, A., Prasad, R., Balasubramanian, V., Gupta, N., Gupta, P., 2015. Prevalence of adverse drug reaction with first-line drug among patients treated for pulmonary tuberculosis. *Clinical Epidemiology and Global Health*, Vol. 112 p. 11
- Solangi, G. A., Zuberi, B. F., Shaikh, S., Shaikh, W. M., 2004. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. *Journal of College of Physicians and Surgeons Pakistan*, Vol. 14, No. 3, p. 136-138
- Solovic, I., Jonsson, J., Korzeniewska- Koseła, M., Chiotan, DI., Pace-Asciak, A., Slump, E., Rumetshofer, R., Abubakar, I., Kos, S., Svetina-Sorli, P., Haas, W., Bauer, T., Sandgren, A., van der Werf, MJ., 2013. Challenges in diagnosing extrapulmonary tuberculosis in the European Union, 2011. *European Surveillance 2013*, Vol. 18, No. 12
- Subramaniyam, K., Barthakur, R., Natarajan, M., Palaian, S., Chhetri, A. K., Mishra, P., 2005. Ocular Side Effects of Antitubercular drugs-a Focus on Prevention, early detection and management. *Kathmandu University Medical Journal*, Vo. 3., No. 4, p. 438-441
- Suhariani, W., dan Wibisono, B. H., 2015. Pola klinik tuberculosis ekstra paru di RSUP dr. Kariadi Semarang periode Juli 2013-Agustus 2014. *Media Medika Muda*, Vol. 4, No. 4, hal. 1638-1652
- Sunnetcioglu, A., Sunnetcioglu, M., Binici, I., Baran, A. I., Karahocagi, M. K., Saydan, M. R., 2015. Comparative analysis of

- pulmonary and extrapulmonary tuberculosis of 411 cases. *Annals of Clinical Microbiology and Antimicrobials*, Vol. 14, No. 34, p. 1-5
- Taki, H., Ogawa, K., Murakami, T., Nikai, T., 2008. Epidemiological survey of hyperuricemia as an adverse reaction to antituberculous therapy with pyrazinamide. *Kekkai*, Vol. 83, p. 497-501
- Tan, W. C., Ong, C. K., Kang, S. C. L., Razak, M. A., 2007. Two Years Review of Cutaneous Adverse Drug Reaction From First Line Anti-Tuberculous Drugs. *Medical Journal of Malaysia*, Vol. 62, No. 2, p. 143-146
- Tatro, D. S., 2009. *Drug Interaction Facts*. Netherland: Wolters Kluwer Health Inc
- Tattevin, P., Chapplain, J. M., Lesprit, P., Billy, C., Roblot, F., Alfandri, S., Bernard, L., Rouveix, E., Bouvet, E., 2006. Tuberculosis treatment duration in France: from guidelines to daily practice. *European Journal of Internal Medicine*, Vol. 17, p. 427-429
- Tutu, S., Kant, S., Verma, A. K., Sachan, A. K., Nath, R., Kumar, N., Singh, A., Dixit, R. K., 2018. Incidence and pattern of adverse drug reaction (ADRs) in patients treated for tuberculosis under DOTS at a tertiary case hospital of northern india. *International Journal of Pharmaceutical Science and Research*. Vol. 9, No. 11, p. 4950-1955
- Velayani, A. A., and Farnia, P., 2017. *Atlas of Mycobacterium tuberculosis*. United States: Academic Press
- Vorster, M. J., Allwood, B. W., Diacon, A. H., Koegelenberg, C. F. N., 2015. Tuberculous pleural effusions: advances and

- controversies. *Journal of Thoracic Disease*, Vol. 7, No. 6, p. 981-991
- Wallace, J. L., Sharkey, K. A., 2011. Chapter 45: Pharmacotherapy of Gastric Acidity, peptic Ulcers and Gastroesophageal Reflux Disease. In: Brunton, L., Chabner, B., Knollman, B., ***Goodman & Gillman's The Pharmacological Basis of Therapeutics***. 12th Ed. New York: Mc Grew Hill Medical, p. 1310
- Wang, J., Hsueh, P., Wang, S., Jan, I., Lee, L. Liaw, Y., Yang, P., Luh, K., 2007. Disseminated Tuberculosis: a 10 year experience in a Medical Center. *Medicine*, Vol. 86, No. 1, p. 39-46
- Wang, P., Pradhan, K., Zhong, X., Ma, X., 2016. Isoniazid metabolism and hepatotoxicity. *Acta Pharmaceutica Sinica B*
- Widyanto, F. W., 2014. Arthritis gout dan perkembangannya. *Jurnal Ilmu Kesehatan dan Kedokteran Keluarga*, Vol. 10, No. 2, hal. 145-152
- Wincent, M. M., Potrilingam, D., Anagha V., Jacob, S. C., Andhuvan G., 2017. Assessment of Drug Related Problems in Patients with Chronic Diseases in The General Medicine Units of a Tertiary Care Hospital. *International Journal of Pharmacy and Pharmaceutical Science*, Vol. 9, No. 12, p. 194-200
- World Health Organization. 2017. ***Global Tuberculosis Report 2017***. United Kingdom: WHO Press
- World Health Organization. 2018. ***Global Tuberculosis Report 2018***. United Kingdom: WHO Press
- World Health Organization. 2010. ***Treatment of Tuberculosis Guidelines 4th Edition***. United Kingdom: WHO Press

- Yang, T. W., Park, H. O., Jang, H. N., Yang, J. H., Kim, S. H., Moon, S. H., Byun, J. H., Lee, C. E., Kim, J. W., Kang, D. H., 2017. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A Retrospective Study. *Medicine*, Vol. 96, No. 28, p.1-5
- Yee, D., Vallquette, C., Pelletier, M., Parisien, I., Rocher, I., Menzies, D., 2003. Incidence of Serious Side effect From First-Line Antituberculosis Drug among patient treated for active tuberculosis. *Americans Journal of Respiratory and Critical Care Medicine*, Vol. 167, p. 1472-1477
- Zhai, K., Lu, Y., Shi, H., 2016. Tuberculous pleural effusion. *Journal of Thoracic Disease*, Vol. 8, No. 7, p. 486-494
- Zhang, X., Andersen, A. B., Lillebaek, T., Kamper-Jorgensen, Z., Thomsen, V. O., Ladefoged, K., Marrs, C. F., Zhang, L., Yang, Z., 2011. Effect of Sex, Age and Race on the Clinical Presentation of Tuberculosis: a 15-Year population-based study. *The American Journal of Tropical Medicine Hygiene* Vol. 85, No. 2, p. 285-290